Comera Life Sciences Holdings, Inc.

As of September 30, 2023, Comera Life Sciences Holdings, Inc. carries a market capitalization of 8.96M, placing it among publicly traded companies globally. Its enterprise value stands at 7.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2023, Comera Life Sciences Holdings, Inc. has 30.74M shares outstanding.

These figures are as of September 30, 2023. The price-to-sales ratio is 5.68, and the price-to-book ratio stands at -2.12.

These figures are as of September 30, 2023. The EV/Sales ratio of 7.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.36M versus a market cap of 8.96M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2023, Comera Life Sciences Holdings, Inc. maintains a current ratio of 0.90, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -4.07, indicating conservative leverage, while an interest coverage ratio of -359.32 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) is negative at -224.98, reflecting losses generated across the asset base. The company generates approximately 76,953.85 in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers.

As of the close on September 24, 2026, Comera Life Sciences Holdings, Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.03.

Over the twelve months ended September 30, 2023, Comera Life Sciences Holdings, Inc. generated 1.00M in revenue and converted that into -9.01M in net income, yielding earnings per share of -0.46. EBITDA reached -9.05M, while operating income came in at -9.15M.

As of September 30, 2023, Comera Life Sciences Holdings, Inc. holds 1.77M in cash and equivalents against 171,596.00 in total debt, resulting in a net debt position of -1.77M. Total book value stands at -4.22M, with working capital of -301,923.00 providing operational flexibility.

Comera Life Sciences Holdings, Inc. produced -6.66M in operating cash flow over the twelve months ended September 30, 2023. After subtracting -94,009.00 in capital expenditures, free cash flow totaled -6.76M - equivalent to -0.35 per share.

Over the twelve months ended September 30, 2023, Comera Life Sciences Holdings, Inc. posted a gross margin of 73.52, reflecting its pricing power and cost economics. The operating margin of -914.32 and net profit margin of -900.56 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -118.85: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -65.33, meaning Comera Life Sciences Holdings, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of September 30, 2023, Comera Life Sciences Holdings, Inc. has an Altman Z-Score of -27.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.